

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
19 December 2002 (19.12.2002)

PCT

(10) International Publication Number
WO 02/100414 A1

- (51) International Patent Classification⁷: **A61K 31/655**, A61P 7/12
- (21) International Application Number: PCT/GB02/02635
- (22) International Filing Date: 7 June 2002 (07.06.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0114008.6 8 June 2001 (08.06.2001) GB
- (71) Applicant (for all designated States except US): **PERRY, Robert, Edward** [GB/GB]; Gill Jennings & Every, Broadgate House, 7 Eldon Street, London EC2M 7LH (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **GRISTWOOD, Robert, William** [GB/GB]; Arachnova Limited, St. John's Innovation Centre, Cambridge CB4 0WS (GB). **CAVALLA, David** [GB/GB]; Arachnova Limited, St. John's Innovation Centre, Cambridge CB4 0WS (GB).
- (74) Agent: **GILL JENNINGS & EVERY**; Broadgate House, 7 Eldon Street, London EC2M 7LH (GB).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/100414 A1

(54) Title: ARYLAZO-SUBSTITUTED IMIDAZOLE FOR THE TREATMENT OF STRESS URINARY INCONTINENCE


(57) Abstract: An arylazo-substituted imidazole having adrenergic alpha stimulatory activity, is useful for the treatment of stress urinary incontinence.

ARYLAZO-SUBSTITUED IMIDAZOLE FOR THE
TREATMENT OF STRESS URINARY INCONTINENCEField of the Invention

This invention relates to a new use for known compounds.

Background of the Invention

5 Arylazo-substituted imidazoles are known. For example, US-A-4315003 discloses 2-[(2-methoxyphenyl)azo]-1H-imidazole derivatives of the formula



15 wherein X is H or halogen, and their therapeutic use in the treatment of edema, hypotension, cardiac insufficiency and mucosa hypermia. Ohnishi *et al*, *Arzneim. Forsch/Drug Research* 31 (ii): 1425-1429, discloses such a compound, i.e. 2-[(5-chloro-2-methoxyphenyl)azo]-1H-imidazole. It is described as a sympathomimetic agent resulting from direct adrenergic alpha stimulation, and
20 Ohnishi *et al* conclude that it is of potential use for the treatment of hypotensive disorders.

2-[(5-Chloro-2-methoxyphenyl)azo]-1H-imidazole is currently considered to be a non-subtype-selective alpha 1 adrenoceptor agonist (hereafter "alpha agonist"; see Tocris catalogue 2001 of Tocris Cookson Ltd., Bristol, UK, Table
25 1, page 20). The compound is referred to in this catalogue as a hypertensive agent (page 243) and is commercially available from Tocris as a research tool. Considerations as to the selectivity of the compound are based on published studies using laboratory animal species.

Alpha 1 agonists in general cause smooth muscle contraction and thereby
30 increase smooth muscle tone, for example in blood vessels or in the lower urinary tract. The alpha 1 receptors are currently divided into 4 subtypes, these being alpha 1A, alpha 1L (possibly a related receptor), alpha 1B and alpha 1D.

Within a species, different tissues may contain a predominance of a particular alpha 1 receptor subtype. It is also known that there is a marked species dependency in the tissue distribution of adrenergic alpha 1 subtypes.

For the clinical treatment of stress urinary incontinence, efficacious agents are required which are selective for increasing the muscle tone of the lower urinary tract and which are relatively free of effects on the cardiovascular system. Recent science indicates that, for this to be achieved in the clinic, a compound with selectivity for the alpha 1A (and or 1L) receptors present in lower urinary tract (LUT) over alpha 1B receptors (present in human blood vessels) is required. Non-selective agonists will have side-effects (particularly cardiovascular), due to the activation of alpha 1B receptors, resulting in increases in vascular tone and undesirable increases in blood pressure.

Because of the species differences referred to above, studies with human tissues are currently required to see whether a compound is efficacious against human LUT smooth muscle and has selectivity in this effect compared with effects on human blood vessels. Insofar as any conclusions can or should be drawn from available data, any efficacy of 2-[(5-chloro-2-methoxyphenyl)azo]-1H-imidazole on human LUT tissues would be associated with an undesirable elevation in blood pressure.

20 Summary of the Invention

Surprisingly, it has now been found that 2-[(5-chloro-2-methoxyphenyl)azo]-1H-imidazole has the desired selective activity, in that it is active at increasing the tone of human LUT tissue whilst being much less active at increasing the tone of human arterial blood vessels. These data indicate that the compound will be useful in the treatment of stress urinary incontinence in man. More generally, according to the present invention, an arylazo-substituted imidazole having adrenergic alpha stimulatory activity is useful in the treatment of stress urinary incontinence.

Description of Invention

30 Any arylazo-substituted imidazole may be used in this invention, provided that it has the desired activity. Its adrenergic alpha stimulatory activity may be determined by known assays, and is preferably at least substantially as for

noradrenaline. This activity is preferably at least 50% of the activity exhibited by 2-[(5-chloro-2-methoxyphenyl)azo]-1H-imidazole.

Preferred agents for use in the invention have one or more structural characteristics of the formula shown above. Most preferably, the compound is
5 2-[(5-chloro-2-methoxyphenyl)azo]-1H-imidazole (X = Cl).

By means of the invention, stress urinary incontinence in humans can be treated, e.g. controlled or prevented. For this purpose, the active compound can be formulated in any suitable manner, together with a conventional diluent or carrier, e.g. as a tablet or capsule, or as a sustained release formulation. The
10 active compound may be administered by any suitable route, e.g. intravaginal (for which purpose a pessary or ring device may be used), and is preferably administered by the oral route.

Suitable compositions for oral use include tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard
15 or soft capsules, syrups and elixirs. Suitable additives include sweetening agents, flavouring agents, colouring agents and preserving agents. Tablets contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients, e.g. inert diluents such as calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and
20 disintegrating agents, for example corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
25 For example, a time delay material such as glyceryl monostearate or glyceryl distearate may be employed. They may also be coated, to form osmotic therapeutic tablets for controlled release. Hard gelatin capsules may include an inert solid diluent, for example calcium carbonate, calcium phosphate or kaolin; soft gelatin capsules may include water or an oil medium, for example peanut oil,
30 liquid paraffin or olive oil.

The amount of active agent to be administered can be readily determined by the skilled person, and will depend on the usual factor such as the frequency

of dosing, the age and condition of the patient, the nature and degree of the complaint, the rate of administration, coadministered drugs etc. A typical daily dosage may be 0.1-1000, e.g. 1-100, mg.

The data on which this invention is based will now be described.

5 Test System

Determinations were made of agonist potency on human LUT and blood vessel smooth muscle. Tissue sources: human lower urinary tract smooth muscle strips (prostatic/urethral) were obtained from patients undergoing transurethral resection of the prostate procedure for benign prostatic hyperplasia. Human mesenteric arteries (500-750 μm internal diameter) were
10 obtained from patients undergoing bowel resection for carcinoma. Tissues were preserved in Krebs-bicarbonate solution at 4°C from the time of surgery until used in functional experiments within 24 hours.

Protocol

15 Sections of mesenteric artery (5 mm in length) were set up between stainless steel stirrups after removal of the endothelium by gentle rubbing. Strips of prostatic/urethral smooth muscle (3 x 10 mm) and the mesenteric arteries were set up under 1 g resting tension in Krebs solution of composition (mM): NaCl 118.4; KCl 4.7; CaCl₂ 1.9; NaHCO₃ 25.0; MgSO₄ 1.2; KH₂PO₄ 1.2;
20 glucose 11.7, gassed with 5% CO₂ in O₂ and maintained at 37°C. The tension developed by all tissues was measured by means of isometric force transducers (Lectromed UF1 57G sensitivity) and recorded to computer *via* a Cambridge Electronic Design 1401 analogue to digital converter, using CHART software. Tissues were equilibrated for 60 minutes with several changes of bathing
25 medium prior to starting drug administrations. All experiments were performed in the presence of cocaine (10 μM) and corticosterone (10 μM), to prevent neuronal and extraneuronal uptake of drugs, and propranolol (1 μM), to block B adrenoreceptors.

Agonist Responses

30 Cumulative concentration-response curves were obtained to 2-[(5-chloro-2-methoxyphenyl)azo]-1H-imidazole, and to noradrenaline for comparison.

For the LUT tissue following recording of the final drug response to noradrenaline or 2-[(5-chloro-2-methoxyphenyl)azo]-1H-imidazole, 100 μ M KCl was added to indicate the maximum ability of the tissue to respond.

For the mesenteric artery preparations following the recording of the final
5 drug response to 2-[(5-chloro-2-methoxyphenyl)azo]-1H-imidazole, a supramaximal concentration of noradrenaline was added as a further test for partial agonism.

Data Analysis

Increases in developed tension to agonist were plotted and individual
10 EC50 values were determined. From these, pEC50 (negative log of the EC50) values were determined for each experiment and where appropriate mean values of these with standard error of the means calculated.

2-[(5-Chloro-2-methoxyphenyl)azo]-1H-imidazole was active on the LUT (appearing a full agonist compared with noradrenaline) tissue and less active on
15 the blood vessels (appearing a partial agonist compared with noradrenaline).


On LUT, both drugs produced concentration-related increases in tension, indicating contraction of the tissue. Noradrenaline had a pEC50 of 5.4 ± 0.39 and produced a maximum response equivalent to $63.7 \pm 4.8\%$ of the response to 100 mM potassium chloride (n=3). 2-[(5-Chloro-2-methoxyphenyl)azo]-1H-
20 imidazole had a pEC50 of 5.7 with a maximum response equivalent to 62.5% of the response to 100 mM potassium chloride. These data indicate that on human LUT 2-[(5-chloro-2-methoxyphenyl)azo]-1H-imidazole is at least as potent as noradrenaline with a similar maximum effect.

On mesenteric arteries, both drugs produced concentration-related
25 increases in tension, indicating contraction of the tissue. Noradrenaline had a pEC50 of 6.18 ± 0.32 with a mean maximum contraction of 4.22 ± 2.21 g (n=10). 2-[(5-Chloro-2-methoxyphenyl)azo]-1H-imidazole had a pEC50 of 5.3 ± 0.1 with a mean maximal contraction (occurring at 20 micromolar) of 1.1 ± 0.7 g (n=3). No further increase in mean tension occurred with higher concentrations of 2-[(5-
30 chloro-2-methoxyphenyl)azo]-1H-imidazole. These data show 2-[(5-chloro-2-methoxyphenyl)azo]-1H-imidazole to be weaker than noradrenaline on the blood vessels and to have a much lower maximum effect, consistent with 2-[(5-chloro-

2-methoxyphenyl)azo]-1H-imidazole being a partial agonist on this tissue. Further evidence that 2-[(5-chloro-2-methoxyphenyl)azo]-1H-imidazole is a partial agonist compared with noradrenaline was obtained. Once the highest concentration of 2-[(5-chloro-2-methoxyphenyl)azo]-1H-imidazole had been administered and the maximum effect defined, a concentration of noradrenaline (160-210 μM) known to be capable of producing a maximum response was added to the organ bath. In all cases, large further increases in tension were produced by the noradrenaline, with a mean further increase of 2.7 ± 0.9 g ($n=3$).

CLAIMS

1. Use of an arylazo-substituted imidazole having adrenergic alpha stimulatory activity, for the manufacture of a medicament for the treatment of stress urinary incontinence.
- 5 2. Use according to claim 1, wherein the imidazole has the formula



wherein X is H or halogen.

- 15 3. Use according to claim 1, wherein the imidazole is 2-[(5-chloro-2-methoxyphenyl)azo]-1H-imidazole.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 02/02635

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61K31/655 A61P7/12

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, BIOSIS, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	RADLEY S C ET AL: "Effect of methoxamine on maximum urethral pressure in women with genuine stress incontinence: A placebo-controlled, double-blind crossover study." NEUROUROLOGY AND URODYNAMICS, vol. 20, no. 1, 2001, pages 43-52, XP001106932 ISSN: 0733-2467 page 45 -page 50 abstract --- -/--	1-3

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

° Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

15 October 2002

Date of mailing of the international search report

05/11/2002

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Felder, C

INTERNATIONAL SEARCH REPORT

International Application No

PCT/GB 02/02635

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	<p>ANDERSSON K E: "Drug therapy for urinary incontinence." BAILLIERE'S BEST PRACTICE & RESEARCH. CLINICAL OBSTETRICS & GYNAECOLOGY. ENGLAND APR 2000, vol. 14, no. 2, April 2000 (2000-04), pages 291-313, XP001106765 ISSN: 1521-6934 page 303 -page 304 page 301, paragraph 3 abstract</p>	1-3
Y	<p>--- NISHIMATSU H ET AL: "Contractile responses to alpha1-adrenoceptor agonists in isolated human male and female urethra" BIOSIS, XP002149903 abstract</p>	1-3
Y	<p>--- OHNISHI H ET AL: "Pharmacological properties of 2-(5-chloro-2-methoxyphenyl)azo-1H-imidazole (M6434)." ARZNEIMITTEL-FORSCHUNG. GERMANY, WEST 1981, vol. 31, no. 9, 1981, pages 1425-1429, XP001106744 ISSN: 0004-4172 page 1428, right-hand column, last paragraph -page 1429, right-hand column, last paragraph abstract</p>	1-3
Y	<p>--- NAKASHIMA M ET AL: "EFFECTS OF 2-5 CHLORO-2-METHOXYPHENYL AZO-1H-IMIDAZOLE M-6434 ON ALPHA ADRENERGIC RECEPTORS" JAPANESE JOURNAL OF PHARMACOLOGY, vol. 45, no. 4, 1987, pages 507-512, XP001106737 ISSN: 0021-5198 page 510, right-hand column, last paragraph -page 511, right-hand column, last paragraph abstract</p>	1-3
	<p>--- -/--</p>	

INTERNATIONAL SEARCH REPORT

 International Application No
 PCT/GB 02/02635

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	DATABASE BIOSIS 'Online! BIOSCIENCES INFORMATION SERVICE, PHILADELPHIA, PA, US; 1992 DABASAKI TATSUROH ET AL: "Effects of M6434, an orally active alpha-1-adrenoceptor agonist, on experimental postural hypotension in rabbits and dogs." Database accession no. PREV199395065463 XP002216105 abstract & FOLIA PHARMACOLOGICA JAPONICA, vol. 100, no. 5, 1992, pages 433-444, ISSN: 0015-5691	1-3
P, Y	--- US 2001/039255 A1 (BRIONI JORGE D ET AL) 8 November 2001 (2001-11-08) paragraph '0019! - paragraph '0020! paragraph '0013! abstract	1-3
A	--- US 4 315 003 A (MOCHIDA EI ET AL) 9 February 1982 (1982-02-09) cited in the application the whole document -----	1-3

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/GB 02/02635

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 2001039255	A1	08-11-2001	NONE
<hr style="border-top: 1px dashed black;"/>			
US 4315003	A	09-02-1982	JP 1334241 C 28-08-1986
			JP 56020516 A 26-02-1981
			JP 60056123 B 09-12-1985
			DE 3028927 A1 26-02-1981
			FR 2462161 A1 13-02-1981
			GB 2057874 A , B 08-04-1981
			US 4507237 A 26-03-1985
<hr style="border-top: 1px dashed black;"/>			